AR098337A1 - Triazolopirazina - Google Patents

Triazolopirazina

Info

Publication number
AR098337A1
AR098337A1 ARP140104188A ARP140104188A AR098337A1 AR 098337 A1 AR098337 A1 AR 098337A1 AR P140104188 A ARP140104188 A AR P140104188A AR P140104188 A ARP140104188 A AR P140104188A AR 098337 A1 AR098337 A1 AR 098337A1
Authority
AR
Argentina
Prior art keywords
3alkyl
optionally
3haloalkyl
halogen
groups independently
Prior art date
Application number
ARP140104188A
Other languages
English (en)
Spanish (es)
Inventor
Engelhardt Harald
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR098337A1 publication Critical patent/AR098337A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP140104188A 2013-11-07 2014-11-06 Triazolopirazina AR098337A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13192002 2013-11-07

Publications (1)

Publication Number Publication Date
AR098337A1 true AR098337A1 (es) 2016-05-26

Family

ID=49518874

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104188A AR098337A1 (es) 2013-11-07 2014-11-06 Triazolopirazina

Country Status (7)

Country Link
US (1) US9428513B2 (enExample)
EP (1) EP3066104B1 (enExample)
JP (1) JP6370376B2 (enExample)
AR (1) AR098337A1 (enExample)
TW (1) TW201609731A (enExample)
UY (1) UY35827A (enExample)
WO (1) WO2015067770A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP7269731B2 (ja) 2015-03-18 2023-05-09 アルビナス・オペレーションズ・インコーポレイテッド 標的タンパク質の分解向上のための化合物および方法
CN108137507A (zh) 2015-07-10 2018-06-08 阿尔维纳斯股份有限公司 基于mdm2的蛋白水解调节剂和相关的使用方法
AU2016301196B2 (en) 2015-08-06 2022-09-08 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
ES3037659T3 (en) 2016-03-30 2025-10-03 Wisconsin Alumni Res Found Methods and compositions for modulating frataxin expression
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
EP3580212A4 (en) 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. REGULATION OF CHEMERIC ANTIGEN RECEPTORS
WO2018183679A1 (en) 2017-03-29 2018-10-04 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
EP3641762B1 (en) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019145410A1 (en) * 2018-01-25 2019-08-01 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
EP3774772A1 (en) 2018-04-13 2021-02-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
EP4077309A1 (en) 2019-12-19 2022-10-26 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9651198A (en) * 1997-11-11 1999-05-31 Ono Pharmaceutical Co. Ltd. Fused pyrazine compounds
EP1598353A1 (en) * 2004-05-17 2005-11-23 Boehringer Ingelheim International GmbH Pyrrolobenzimidazolones and their use as antiproliferative agents
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2496580B1 (en) 2009-11-05 2013-12-11 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors

Also Published As

Publication number Publication date
UY35827A (es) 2015-05-29
US9428513B2 (en) 2016-08-30
TW201609731A (zh) 2016-03-16
WO2015067770A1 (en) 2015-05-14
JP2016540742A (ja) 2016-12-28
EP3066104A1 (en) 2016-09-14
US20150133447A1 (en) 2015-05-14
EP3066104B1 (en) 2017-12-06
JP6370376B2 (ja) 2018-08-08

Similar Documents

Publication Publication Date Title
AR119454A2 (es) COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR097436A1 (es) Bis-amidopiridinas
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
AR090159A1 (es) 5-alquinil piridinas
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR097435A1 (es) 6-alquinilpiridinas
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
AR089776A1 (es) 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
AR099363A1 (es) Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas
AR101479A1 (es) Derivados de 6-alquinil-piridina
AR106798A1 (es) Inhibidores pirazol de acc y usos de los mismos
AR097008A1 (es) Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR101600A1 (es) COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
AR090230A1 (es) Derivados macrociclicos para el tratamiento de enfermedades
UY35377A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
PY1411052A (es) Compuestos heterocíclicos y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure